Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 10/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464873 | 1.00 | CCR1 (0.51) | CCR1CXCR3MAPTCHRM1CYP2C19 | |
| SCHEMBL3463483 | 0.88 | CCR1 (0.56) | CCR1CXCR3CYP2C19KCNH2 | |
| SCHEMBL3463484 | 0.88 | CCR1 (0.56) | CCR1CXCR3CYP2C19KCNH2 | |
| SCHEMBL12726530 | 0.85 | CCR1 (0.51) | CCR1CXCR3CHRM1 | |
| SCHEMBL1637737 | 0.85 | CCR1 (0.51) | CCR1CXCR3CHRM1 | |
| SCHEMBL3464619 | 0.85 | CCR1 (0.49) | CCR1CXCR3CHRM1 | |
| SCHEMBL3464621 | 0.85 | CCR1 (0.49) | CCR1CXCR3CHRM1 | |
| SCHEMBL3864970 | 0.84 | CCR1 (0.55) | CCR1CXCR3CYP2C19KCNH2 | |
| SCHEMBL3864967 | 0.84 | CCR1 (0.55) | CCR1CXCR3CYP2C19KCNH2 | |
| SCHEMBL3464356 | 0.82 | CCR1 (0.59) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885CXCR3 18/4885MAPT 4063/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | CCR1 1/4885CXCR3 18/4885MAPT 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.